The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids.
The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids.
复制标题
DOI:
10.1016/j.ijpharm.2013.05.053
复制
发表时间:
2013-09
影响因子:
5.8
通讯作者:
Ye Tian;Sainan Qian;Yan Jiang;Qian Shen;Jiang Zheng;Hui Zhou;S. Zeng
中科院分区:
文献类型:
--
作者:
Ye Tian;Sainan Qian;Yan Jiang;Qian Shen;Jiang Zheng;Hui Zhou;S. Zeng
BCRP is one of the key factors to drug absorption, distribution and elimination. Bisbenzylisoquinoline alkaloids are a large family of natural phytochemicals with great potential for clinical use. In this study, the interaction between BCRP and five bisbenzylisoquinoline alkaloids (neferine, isoliensinine, liensinine, dauricine and tetrandrine) were evaluated using LLC-PK1/BCRP cell model. The intracellular accumulation and bi-directional transport studies were conducted, and then molecular docking analysis was carried out employing a homology model of BCRP. Our study revealed that the permeability of these five alkaloids was not high, thePappvalues were all less than 6.5 × 10−6cm/s. Liensinine and dauricine were substrates of BCRP: at lower concentration (10 μM), the net efflux ratios were 2.87 and 1.64 respectively. And their cellular accumulation was lower in LLC-PK1/BCRP cells than in LLC-PK1 cells. On the other hand, tetrandrine, isoliensinine and neferine were not substrates of BCRP. On the basis of docking studies, a direct hydrogen bond was formed between liensinine and arginine 482 which is a hot spot of BCRP for substrate specificity; and dauricine had hydrophobic interaction with BCRP. In conclusion, our study indicated that BCRP could mediate the excretion of liensinine and dauricine, thus influence their pharmacological activity and disposition.